Incremental Reduction in Risk of Death Associated With Use of Guideline‐Recommended Therapies in Patients With Heart Failure: A Nested Case‐Control Analysis of IMPROVE HF

Author:

Fonarow Gregg C.1,Albert Nancy M.2,Curtis Anne B.3,Gheorghiade Mihai4,Liu Yang5,Mehra Mandeep R.6,O'Connor Christopher M.7,Reynolds Dwight8,Walsh Mary N.9,Yancy Clyde W.10

Affiliation:

1. From the Ahmanson‐UCLA Cardiomyopathy Center, Ronald Reagan UCLA Medical Center, Los Angeles, CA

2. Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, OH

3. Department of Medicine, University at Buffalo, Buffalo, NY

4. Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL

5. Department of Statistics, CRDM, Medtronic, Inc, Mounds View, MN

6. Division of Cardiology, Harvard Medical School, Boston, MA

7. Division of Cardiology, Duke University Medical Center, Durham, NC

8. Division of Cardiology, University of Oklahoma Health Sciences Center, Oklahoma City

9. The Care Group, St Vincent Heart Center of Indiana, Indianapolis, IN

10. Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL

Abstract

Background Several therapies are guideline‐recommended to reduce mortality in patients with heart failure (HF) and reduced left ventricular ejection fraction, but the incremental clinical effectiveness of these therapies has not been well studied. We aimed to evaluate the individual and incremental benefits of guideline‐recommended HF therapies associated with 24‐month survival. Methods and Results We performed a nested case‐control study of HF patients enrolled in IMPROVE HF. Cases were patients who died within 24 months and controls were patients who survived to 24 months, propensity‐matched 1:2 for multiple prognostic variables. Logistic regression was performed, and the attributable mortality risk from incomplete application of each evidence‐based therapy among eligible patients was calculated. A total of 1376 cases and 2752 matched controls were identified. β‐Blocker and cardiac resynchronization therapy were associated with the greatest 24‐month survival benefit (adjusted odds ratio for death 0.42, 95% confidence interval (CI), 0.34–0.52; and 0.44, 95% CI, 0.29–0.67, respectively). Angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers, implantable cardioverter‐defibrillators, anticoagulation for atrial fibrillation, and HF education were also associated with benefit, whereas aldosterone antagonist use was not. Incremental benefits were observed with each successive therapy, plateauing once any 4 to 5 therapies were provided (adjusted odds ratio 0.31, 95% CI, 0.23–0.42 for 5 or more versus 0/1, P <0.0001). Conclusions Individual, with a single exception, and incremental use of guideline‐recommended therapies was associated with survival benefit, with a potential plateau at 4 to 5 therapies. These data provide further rationale to implement guideline‐recommended HF therapies in the absence of contraindications to patients with HF and reduced left ventricular ejection fraction.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Cited by 75 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3